PRESS RELEASES

Found 251 Results
Page 2 of 26

Onxeo Announces Approval of the REVocan Study By Regulatory Authorities


The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]

Tags:

05/29/2020


Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation


Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

05/27/2020


Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi


Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

05/19/2020


Onxeo’s Joint General Meeting in camera on May 29, 2020: availability of preparatory documents and live webcast login information


Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Tags: ,

05/07/2020


Publication of the 2019 Universal Registration Document


Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Tags:

04/27/2020


Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update


Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended […]

Tags:

04/17/2020


Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC


This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology $6.6m […]

Tags:

04/06/2020


Onxeo Will Publish Its Annual Results on April 17, 2020


The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]

Tags:

03/27/2020


Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020


Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

02/27/2020


Onxeo Enters into Settlement Agreement with SpePharm and SpeBio


Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]

Tags:

02/11/2020


Page 2 of 26

Last updated on